Skip to main content
. 2020 Nov 27;22(1):66–73. doi: 10.1016/S1470-2045(20)30619-7

Figure 1.

Figure 1

Change in systemic anticancer treatment registrations for April–June, 2020, by intended treatment type and line of therapy (A) and tumour type (B)

The number of registrations for April, May, and June, 2020, were compared against the mean number for the control period. *Includes neuroendocrine tumours, thyroid tumours, sarcomas, gastrointestinal stromal tumours, gestational trophoblastic disease, and CNS tumours.